Article Versions Notes

Pleguezuelos P, Sibila M, Cuadrado-Matías R, López-Jiménez R, Pérez D, Huerta E, Pérez M, Correa-Fiz F, Mancera-Gracia JC, Taylor LP, et al. Efficacy Studies of a Trivalent Vaccine Containing PCV-2a, PCV-2b Genotypes and Mycoplasma hyopneumoniae When Administered at 3 Days of Age and 3 Weeks Later against Porcine Circovirus 2 (PCV-2) Infection. Vaccines. 2022; 10(8):1234. https://doi.org/10.3390/vaccines10081234

Pleguezuelos, Patricia, Marina Sibila, Raúl Cuadrado-Matías, Rosa López-Jiménez, Diego Pérez, Eva Huerta, Mónica Pérez, Florencia Correa-Fiz, José Carlos Mancera-Gracia, Lucas P. Taylor, and et al. 2022. "Efficacy Studies of a Trivalent Vaccine Containing PCV-2a, PCV-2b Genotypes and Mycoplasma hyopneumoniae When Administered at 3 Days of Age and 3 Weeks Later against Porcine Circovirus 2 (PCV-2) Infection" Vaccines 10, no. 8: 1234. https://doi.org/10.3390/vaccines10081234

Pleguezuelos, P., Sibila, M., Cuadrado-Matías, R., López-Jiménez, R., Pérez, D., Huerta, E., Pérez, M., Correa-Fiz, F., Mancera-Gracia, J. C., Taylor, L. P., Borowski, S., Saunders, G., Segalés, J., López-Soria, S., & Balasch, M. (2022). Efficacy Studies of a Trivalent Vaccine Containing PCV-2a, PCV-2b Genotypes and Mycoplasma hyopneumoniae When Administered at 3 Days of Age and 3 Weeks Later against Porcine Circovirus 2 (PCV-2) Infection. Vaccines, 10(8), 1234. https://doi.org/10.3390/vaccines10081234